Vertex Pharmaceuticals (MA) Completes Redemption of Convertible Senior Subordinated Notes

Published: Jun 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015. Holders of $400 million in aggregate principal amount of the 2015 Notes converted their 2015 Notes into approximately 8.3 million shares of common stock prior to the June 17, 2013 redemption date. With the completion of this transaction, Vertex has no outstanding convertible debt.

Help employers find you! Check out all the jobs and post your resume.

Back to news